Juniper Publishers: JAK2 and Its Regulators beyond Myeloproliferative ...

Juniper Publishers: JAK2 and Its Regulators beyond Myeloproliferative ...: JUNIPER PUBLISHERS-Journal of Tumor Medicine & Prevention JAK2 and Its Regulators beyond Myeloproliferative Neoplasms Aut...

Comments

Post a Comment

Popular posts from this blog

Juniper Publishers| The Anatomical Architecture of the Junction between the Great Cerebral Vein and the Straight Sinus in Correlation to the Physiological and Biochemical Impact on Multiple Sclerosis Subtypes and Disease Progression- A Review Article

Image
  Journal of Surgery -  JuniperPublishers Abstract Introduction:  Multiple Sclerosis (MS) is a debilitating autoimmune disorder, characterized by damage to the white matter of the central nervous system. Studies suggest a relationship between impaired cerebral venous blood flow and progressive destruction of white matter in the CNS. Altered cerebral venous architecture is a possible mechanism that may contribute to a compromised venous blood flow pattern in MS patients. Natural variations at junction located between the great cerebral vein (GCV) and the straight sinus (Ss) located within the cerebral venous drainage system can potentially exacerbate MS progression. Recent data indicates that abnormal cerebral venous hemodynamics contributes to the pathophysiology observed in MS through an unknown mechanism that increases hydraulic resistance. Objective:  This review aims to investigate if anatomical variations at the GSV and Ss junction elicit a profound effect on the cerebral venous s
Read more

Juniper Publishers| The Use of the Second-Generation Protein Kinase Inhibitors in Patients with Gastrointestinal Stromal Tumor with Failure to the Treatment with Imatinib

  Journal of Surgery -  JuniperPublishers Introduction:  Gastrointestinal Stromal Tumor (GIST) is considered the most common mesenchymal tumor of the gastrointestinal tract. Approximately 85% of GISTs have mutations in proto-oncogene KIT encoding, a tyrosine kinase receptor. About 8% of GISTs are associated to mutations in the growth factor receptor alpha (PDGFRA) gene. The standard treatment of GIST is the surgical resection of the tumor. In cases of metastasis and tumor recurrence specific drugs as tyrosine kinase inhibitors are used. The first line treatment is Imatinib. Although the treatment with imatinib failed in some patients for the metastatic and relapsed treatment of GIST, the patients can to use other drugs, called second generation. Discussion:  One of the great advances in the diagnosis of GIST was the recognition through the immunohistochemistry of the c-Kit marker. The tyrosine kinase inhibitor, imatinib, has become the standard treatment for those, with high-risk resec
Read more